MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Sartorius Stedim Biotech S.A.
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Sartorius Stedim Biotech Introduces BIOSTAT® RM TX with Flexsafe® RM TX for Producing Consistent Quality Cellular Products - Sartorius Stedim Biotech (SSB) announced the launch of the BIOSTAT® RM TX single-use bioreactor - Phacilitate.co.uk / Sartorius.com
Sartorius Stedim Biotech Introduces BIOSTAT® RM TX with Flexsafe® RM TX for Producing Consistent Quality Cellular Products

 

NewswireToday - /newswire/ - Göttingen, Lower Saxony, Germany, 2019/01/21 - Sartorius Stedim Biotech (SSB) announced the launch of the BIOSTAT® RM TX single-use bioreactor - Phacilitate.co.uk / Sartorius.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

• New rocking motion single-use bioreactor system to culture cell products in working volumes up to 5 L;
• Flexsafe® RM TX bags enable reliable process performance for optimal cell growth;
• Premiers at Phacilitate Leaders World 2019 in Miami.

Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry today announced the launch of the BIOSTAT® RM TX single-use bioreactor, a new wave mixed system developed specifically for closed, automated expansion of consistent quality cell products such as ex vivo cellular immunotherapies. This new GMP platform, which combines SSB’s established single-use Flexsafe® bag technology with the company’s expertise in biopharmaceutical automation, will be introduced at Phacilitate Leaders World 2019 (phacilitate.co.uk) in Miami, USA (January 22-25 / Booth 410).

SSB’s new bioreactor is designed for scale-out expansion of cells including patient-specific
T cells and is a closed system, consisting of an automated control unit and a up to two rocking platforms to gently agitate single-use Flexsafe® RM TX bags (up to 5L working volume). The bag is the core of the system and built on SSB’s Flexsafe® film, which is already well-established from clinical development to GMP manufacturing of vaccines and biologics by major global biopharma companies. The film formulation is developed to minimize leachables and extractables, guaranteeing consistent batch-to-batch culture performance of even sensitive cell types, such as genetically modified T cells.

The proprietary Flexsafe® RM TX bag is designed with a special port for hands-free gravity harvesting. In combination with the innovative Flexsafe® RM TX Harvest Device it reduces the contamination risks from manual handling, maintaining cell integrity and cell viability. Unlike other cell therapy expansion systems which use pumps for cell recovery, this unique gravity harvest concept reduces the risk of shear stress on these delicate cells, to maximize cell number recovery.

A benefit of using the BIOSTAT® RM TX bioreactor in combination with the Flexsafe® RM TX bag for cell culture is the possibility for walk-away monitoring and culture control. The bags include single-use sensors for pH, DO and viable biomass. These sensors are integrated in the BIOSTAT® B control unit, and the system’s sophisticated software is set-up for fully automated process control of gases, flow rate, filling volume and substrate addition. With culture volumes greater than 500 mL, on-line analysis of viable biomass is also possible by connecting the single-use BioPAT® ViaMass sensor. These sensors make the system suitable for running continuously in fed-batch or perfusion modes, saving labor, time and effort with manual sampling and also minimizing contamination risks to precious patient cells.

Utilizing this bioreactor system, manufacturers can attach a second rocking platform and Flexsafe® RM TX bag to each BIOSTAT® B control unit to scale-out their production. The system also provides a standard interface to common Supervisory Control and Data Acquisition as well as Distributed Control Systems such as BioPAT® MFCS and DeltaV™.

“Combining single-use technology with advanced automation for the expansion of cell products ensures control of process variability and enables safe, robust and affordable cell production,” explained Dr. Franziska Faulstich, Global Product Manager Regenerative Medicine and RM Bioreactors at Sartorius Stedim Biotech. “Working extensively with leaders in the cellular immunotherapy field, we have identified the right technologies and best practice workflows, which we have incorporated into our new BIOSTAT® RM TX bioreactor,” she added.

Cell product developers visiting Booth 410 at Phacilitate World Leaders 2019 will discover how using this cleverly designed system can help improve their process performance, and as a result the integrity and consistency of their promising cell therapies in development.

BIOSTAT® RM TX and Flexsafe® RM TX bags are for research and further manufacturing use only not for use in therapeutic or diagnostic procedures. They are not CE marked for in vitro diagnostic use nor are they medical devices. Drug manufacturers and clinicians are responsible for obtaining the appropriate IND | BLA | NDA approvals for clinical applications.

About Sartorius Stedim Biotech

Sartorius Stedim Biotech (sartorius.com) is a leading international supplier of products and services that enable the biopharmaceutical industry to develop and manufacture drugs safely and efficiently. As a total solutions provider, Sartorius Stedim Biotech offers a portfolio covering nearly all steps of biopharmaceutical manufacture. The company focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech has a global reach. In 2017, the company employed approx. 5,100 people, and earned sales revenue of 1,081 million euros.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Sartorius Stedim Biotech S.A.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Sartorius Stedim Biotech Introduces BIOSTAT® RM TX with Flexsafe® RM TX for Producing Consistent Quality Cellular Products

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Dominic Grone - Sartorius.com 
+49(0)551 308 3324 dominic.grone[.]sartorius.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Sartorius Stedim Biotech S.A. securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Sartorius Stedim Biotech S.A. / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Global Phase 3 Clinical Study of Pridopidine in Huntington’s Disease Announced
Ipsen Showcases Commitment to Patient-centric Advances in Oncology with Record Number of Abstracts to be Presented At ESMO 2020 Virtual Congress
Ipsen to Present New Insights At ASBMR for Potential Treatment of Ultra-rare Disease Fibrodysplasia Ossificans Progressiva (FOP)
Ipsen to Present Results from MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP) At ASBMR 2020 Annual Meeting
DSM Ignites New Strategic Initiative to Transform Global Animal Nutrition and Health
Jamjoom Pharmaceuticals Earns Acclaim from Frost & Sullivan for its Dominance in the KSA Pharma Market
DSM and Avril Complete Creation of Joint Venture to Develop Plant-based Protein
Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-small Cell Lung Cancer
Stevanato Group, SCHOTT, and Gerresheimer Confirm the Readiness to Support Future Covid-19 Vaccine with Pharmaceutical Containers
Ipsen Receives FDA Fast Track Designation for Liposomal Irinotecan (ONIVYDE®) as A First-line Combination Treatment for Metastatic Pancreatic Cancer
Ipsen Demonstrates Continued Commitment to Rare Diseases with Eight Abstracts Accepted At ENDO 2020 Published in the Journal of the Endocrine Society
Waters Corporation Earns New Product Innovation Award with First SmartMS-enabled Biopharmaceutical Solution
DSM Boosts Maternal and Infant Nutrition Portfolio with New Plant-based High Potency DHA Oil
Ipsen Enters into an Option Agreement with IRICoR and Université de Montréal for A Discovery-stage Oncology Program
Ipsen Announces Positive Topline Results from Pivotal Phase III CheckMate -9ER Trial Evaluating CABOMETYX®

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  RightITnow, Inc.





 
  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)